Hemophilia community applauds FDA rejection

The FDA shocked many hematology researchers — and Wall Street onlookers — when it rejected Biomarin’s gene therapy for hemophilia A this week. But many in the hemophilia patient community aren’t saddened by the regulatory decision. Instead, they appreciate it, STAT’s Elizabeth Cooney writes.

“I think it’s good for the patient community because we need to protect our patients at all costs,” one hemophilia advocate told STAT. “This is a community that’s been through a tremendous amount of grief in the past with first HIV and AIDS and then hepatitis C. So I think protecting our community is of the utmost importance. And at this point, there’s just too many unknowns that we don’t understand the answers to.”